Financhill
Buy
85

SLNO Quote, Financials, Valuation and Earnings

Last price:
$73.34
Seasonality move :
2.33%
Day range:
$66.90 - $73.97
52-week range:
$36.61 - $73.97
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3,695.18x
P/B ratio:
13.47x
Volume:
5.1M
Avg. volume:
1.4M
1-year change:
68.2%
Market cap:
$3.3B
Revenue:
--
EPS (TTM):
-$4.26

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
SLNO
Soleno Therapeutics
-- -- -- -- $98.38
AARD
Aardvark Therapeutics
-- -$0.71 -- -- $32.33
CVM
CEL-SCI
-- -- -- -- $8.00
KRYS
Krystal Biotech
$99.2M $1.39 121.14% 497.44% $214.80
LEGN
Legend Biotech
$192.6M -$0.29 104.21% -8.33% $78.01
ME
23andMe Holding
$52M -$4.40 8.6% -11.01% $2.08
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
SLNO
Soleno Therapeutics
$71.99 $98.38 $3.3B -- $0.00 0% 3,695.18x
AARD
Aardvark Therapeutics
$7.74 $32.33 $165.5M -- $0.00 0% --
CVM
CEL-SCI
$0.24 $8.00 $18.4M -- $0.00 0% --
KRYS
Krystal Biotech
$183.92 $214.80 $5.3B 61.51x $0.00 0% 18.80x
LEGN
Legend Biotech
$35.06 $78.01 $6.4B -- $0.00 0% 10.22x
ME
23andMe Holding
$0.61 $2.08 $16.3M -- $0.00 0% 0.07x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
SLNO
Soleno Therapeutics
-- -0.316 -- --
AARD
Aardvark Therapeutics
-- 0.000 -- --
CVM
CEL-SCI
-- 1.534 -- --
KRYS
Krystal Biotech
-- 2.518 -- 6.89x
LEGN
Legend Biotech
22.45% 1.943 5.04% 4.49x
ME
23andMe Holding
-- 0.550 -- 0.74x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
SLNO
Soleno Therapeutics
-- -$58.8M -- -- -- -$24M
AARD
Aardvark Therapeutics
-- -- -- -- -- --
CVM
CEL-SCI
-- -$6.9M -- -- -- -$4.2M
KRYS
Krystal Biotech
$86.2M $41.4M 10.49% 10.49% 45.4% $52M
LEGN
Legend Biotech
$112.6M -$74.4M -12.31% -15.44% 24.48% -$84.5M
ME
23andMe Holding
$39.8M -$25.2M -223.36% -223.36% -41.87% -$46.1M

Soleno Therapeutics vs. Competitors

  • Which has Higher Returns SLNO or AARD?

    Aardvark Therapeutics has a net margin of -- compared to Soleno Therapeutics's net margin of --. Soleno Therapeutics's return on equity of -- beat Aardvark Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    SLNO
    Soleno Therapeutics
    -- -$1.27 --
    AARD
    Aardvark Therapeutics
    -- -- --
  • What do Analysts Say About SLNO or AARD?

    Soleno Therapeutics has a consensus price target of $98.38, signalling upside risk potential of 36.65%. On the other hand Aardvark Therapeutics has an analysts' consensus of $32.33 which suggests that it could grow by 317.74%. Given that Aardvark Therapeutics has higher upside potential than Soleno Therapeutics, analysts believe Aardvark Therapeutics is more attractive than Soleno Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    SLNO
    Soleno Therapeutics
    5 0 0
    AARD
    Aardvark Therapeutics
    2 0 0
  • Is SLNO or AARD More Risky?

    Soleno Therapeutics has a beta of -1.695, which suggesting that the stock is 269.471% less volatile than S&P 500. In comparison Aardvark Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock SLNO or AARD?

    Soleno Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aardvark Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Soleno Therapeutics pays -- of its earnings as a dividend. Aardvark Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios SLNO or AARD?

    Soleno Therapeutics quarterly revenues are --, which are smaller than Aardvark Therapeutics quarterly revenues of --. Soleno Therapeutics's net income of -$56M is higher than Aardvark Therapeutics's net income of --. Notably, Soleno Therapeutics's price-to-earnings ratio is -- while Aardvark Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Soleno Therapeutics is 3,695.18x versus -- for Aardvark Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    SLNO
    Soleno Therapeutics
    3,695.18x -- -- -$56M
    AARD
    Aardvark Therapeutics
    -- -- -- --
  • Which has Higher Returns SLNO or CVM?

    CEL-SCI has a net margin of -- compared to Soleno Therapeutics's net margin of --. Soleno Therapeutics's return on equity of -- beat CEL-SCI's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    SLNO
    Soleno Therapeutics
    -- -$1.27 --
    CVM
    CEL-SCI
    -- -$0.11 --
  • What do Analysts Say About SLNO or CVM?

    Soleno Therapeutics has a consensus price target of $98.38, signalling upside risk potential of 36.65%. On the other hand CEL-SCI has an analysts' consensus of $8.00 which suggests that it could grow by 3251.49%. Given that CEL-SCI has higher upside potential than Soleno Therapeutics, analysts believe CEL-SCI is more attractive than Soleno Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    SLNO
    Soleno Therapeutics
    5 0 0
    CVM
    CEL-SCI
    1 0 0
  • Is SLNO or CVM More Risky?

    Soleno Therapeutics has a beta of -1.695, which suggesting that the stock is 269.471% less volatile than S&P 500. In comparison CEL-SCI has a beta of 0.666, suggesting its less volatile than the S&P 500 by 33.414%.

  • Which is a Better Dividend Stock SLNO or CVM?

    Soleno Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Soleno Therapeutics pays -- of its earnings as a dividend. CEL-SCI pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios SLNO or CVM?

    Soleno Therapeutics quarterly revenues are --, which are smaller than CEL-SCI quarterly revenues of --. Soleno Therapeutics's net income of -$56M is lower than CEL-SCI's net income of -$7.1M. Notably, Soleno Therapeutics's price-to-earnings ratio is -- while CEL-SCI's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Soleno Therapeutics is 3,695.18x versus -- for CEL-SCI. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    SLNO
    Soleno Therapeutics
    3,695.18x -- -- -$56M
    CVM
    CEL-SCI
    -- -- -- -$7.1M
  • Which has Higher Returns SLNO or KRYS?

    Krystal Biotech has a net margin of -- compared to Soleno Therapeutics's net margin of 49.9%. Soleno Therapeutics's return on equity of -- beat Krystal Biotech's return on equity of 10.49%.

    Company Gross Margin Earnings Per Share Invested Capital
    SLNO
    Soleno Therapeutics
    -- -$1.27 --
    KRYS
    Krystal Biotech
    94.57% $1.52 $946.4M
  • What do Analysts Say About SLNO or KRYS?

    Soleno Therapeutics has a consensus price target of $98.38, signalling upside risk potential of 36.65%. On the other hand Krystal Biotech has an analysts' consensus of $214.80 which suggests that it could grow by 16.79%. Given that Soleno Therapeutics has higher upside potential than Krystal Biotech, analysts believe Soleno Therapeutics is more attractive than Krystal Biotech.

    Company Buy Ratings Hold Ratings Sell Ratings
    SLNO
    Soleno Therapeutics
    5 0 0
    KRYS
    Krystal Biotech
    8 1 0
  • Is SLNO or KRYS More Risky?

    Soleno Therapeutics has a beta of -1.695, which suggesting that the stock is 269.471% less volatile than S&P 500. In comparison Krystal Biotech has a beta of 0.870, suggesting its less volatile than the S&P 500 by 12.951%.

  • Which is a Better Dividend Stock SLNO or KRYS?

    Soleno Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Krystal Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Soleno Therapeutics pays -- of its earnings as a dividend. Krystal Biotech pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios SLNO or KRYS?

    Soleno Therapeutics quarterly revenues are --, which are smaller than Krystal Biotech quarterly revenues of $91.1M. Soleno Therapeutics's net income of -$56M is lower than Krystal Biotech's net income of $45.5M. Notably, Soleno Therapeutics's price-to-earnings ratio is -- while Krystal Biotech's PE ratio is 61.51x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Soleno Therapeutics is 3,695.18x versus 18.80x for Krystal Biotech. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    SLNO
    Soleno Therapeutics
    3,695.18x -- -- -$56M
    KRYS
    Krystal Biotech
    18.80x 61.51x $91.1M $45.5M
  • Which has Higher Returns SLNO or LEGN?

    Legend Biotech has a net margin of -- compared to Soleno Therapeutics's net margin of 14.09%. Soleno Therapeutics's return on equity of -- beat Legend Biotech's return on equity of -15.44%.

    Company Gross Margin Earnings Per Share Invested Capital
    SLNO
    Soleno Therapeutics
    -- -$1.27 --
    LEGN
    Legend Biotech
    60.37% $0.14 $1.3B
  • What do Analysts Say About SLNO or LEGN?

    Soleno Therapeutics has a consensus price target of $98.38, signalling upside risk potential of 36.65%. On the other hand Legend Biotech has an analysts' consensus of $78.01 which suggests that it could grow by 122.51%. Given that Legend Biotech has higher upside potential than Soleno Therapeutics, analysts believe Legend Biotech is more attractive than Soleno Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    SLNO
    Soleno Therapeutics
    5 0 0
    LEGN
    Legend Biotech
    11 2 0
  • Is SLNO or LEGN More Risky?

    Soleno Therapeutics has a beta of -1.695, which suggesting that the stock is 269.471% less volatile than S&P 500. In comparison Legend Biotech has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock SLNO or LEGN?

    Soleno Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Legend Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Soleno Therapeutics pays -- of its earnings as a dividend. Legend Biotech pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios SLNO or LEGN?

    Soleno Therapeutics quarterly revenues are --, which are smaller than Legend Biotech quarterly revenues of $186.5M. Soleno Therapeutics's net income of -$56M is lower than Legend Biotech's net income of $26.3M. Notably, Soleno Therapeutics's price-to-earnings ratio is -- while Legend Biotech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Soleno Therapeutics is 3,695.18x versus 10.22x for Legend Biotech. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    SLNO
    Soleno Therapeutics
    3,695.18x -- -- -$56M
    LEGN
    Legend Biotech
    10.22x -- $186.5M $26.3M
  • Which has Higher Returns SLNO or ME?

    23andMe Holding has a net margin of -- compared to Soleno Therapeutics's net margin of -88.01%. Soleno Therapeutics's return on equity of -- beat 23andMe Holding's return on equity of -223.36%.

    Company Gross Margin Earnings Per Share Invested Capital
    SLNO
    Soleno Therapeutics
    -- -$1.27 --
    ME
    23andMe Holding
    66.09% -$2.01 $62.7M
  • What do Analysts Say About SLNO or ME?

    Soleno Therapeutics has a consensus price target of $98.38, signalling upside risk potential of 36.65%. On the other hand 23andMe Holding has an analysts' consensus of $2.08 which suggests that it could grow by 243.07%. Given that 23andMe Holding has higher upside potential than Soleno Therapeutics, analysts believe 23andMe Holding is more attractive than Soleno Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    SLNO
    Soleno Therapeutics
    5 0 0
    ME
    23andMe Holding
    0 0 0
  • Is SLNO or ME More Risky?

    Soleno Therapeutics has a beta of -1.695, which suggesting that the stock is 269.471% less volatile than S&P 500. In comparison 23andMe Holding has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock SLNO or ME?

    Soleno Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. 23andMe Holding offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Soleno Therapeutics pays -- of its earnings as a dividend. 23andMe Holding pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios SLNO or ME?

    Soleno Therapeutics quarterly revenues are --, which are smaller than 23andMe Holding quarterly revenues of $60.3M. Soleno Therapeutics's net income of -$56M is lower than 23andMe Holding's net income of -$53M. Notably, Soleno Therapeutics's price-to-earnings ratio is -- while 23andMe Holding's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Soleno Therapeutics is 3,695.18x versus 0.07x for 23andMe Holding. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    SLNO
    Soleno Therapeutics
    3,695.18x -- -- -$56M
    ME
    23andMe Holding
    0.07x -- $60.3M -$53M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

How High Could IBIT Go?
How High Could IBIT Go?

Recently, a surprising number of billionaire hedge fund managers have…

Is Raymond James Stock a Buy, Sell or Hold?
Is Raymond James Stock a Buy, Sell or Hold?

Raymond James Financial (NYSE:RJF) is one of America’s large financial…

Is JHX Stock a Buy Sell or Hold?
Is JHX Stock a Buy Sell or Hold?

James Hardie Industries (NYSE:JHX) is a manufacturer of outside building…

Stock Ideas

Buy
53
Is AAPL Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 36x

Sell
46
Is MSFT Stock a Buy?

Market Cap: $2.8T
P/E Ratio: 32x

Sell
41
Is NVDA Stock a Buy?

Market Cap: $2.7T
P/E Ratio: 37x

Alerts

Buy
78
AJINY alert for Mar 31

Ajinomoto [AJINY] is down 2.4% over the past day.

Buy
69
AGX alert for Mar 31

Argan [AGX] is down 7.41% over the past day.

Sell
24
AIR alert for Mar 31

AAR [AIR] is down 2.33% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock